Candida is the most common fungal pathogen of humans worldwide and has become a major clinical problem because of the growing number of immunocompromised patients, who are susceptible to infection. Moreover, the number of available antifungals is limited, and antifungal-resistant Candida strains are emerging. New and effective antifungals are therefore urgently needed. Here, we discovered a sma...

BACKGROUND In contrast to the increasing numbers of agents for the treatment of invasive fungal infections, discoveries of new antifungal agents with therapeutic value in dermatomycoses are reported only rarely. METHODS Abafungin (chemical abstracts service registry No. 129639-79/8) is the first member of a novel class of synthetic antifungal compounds, the arylguanidines. It was first synthe...

Oral candidiasis is caused by Candida albicans. The symptoms including pain in the oral cavity affect our eating function. While some antifungal agents are commonly used for the treatment of candidiasis, occasional consumption of the effective dose cannot be tolerated due to side effects. There is also a possibility of induction of antifungal resistance, thus the development of replacement agen...

Fungal infections are affecting millions of people in the world every year. Severity range from superficial mycoses to more chronic systemic mycoses. As fungi species evolve, emergence drug resistant strains is becoming a serious concern public health. There now less number effective antifungal drugs available market for treatment invasive fungal infections. In an effort combat this escalating ...